Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Jack C. Stromatt; Eman Ahmed; Thomas Drabison; Mahesh R. Nepal; Anika T. Chowdhury; Shelley Orwick; Daelynn R. Buelow; Eric D. Eisenmann; Kevin M. Huang; Alex Sparreboom; Sharyn D. Baker

doi:10.1158/2767-9764.30111356

September 12, 2025Open Access

Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

View Full Paper

Ask AI

Bookmark

Share

Key Points

TL-895 influences drug-drug interactions, notably affecting pravastatin and gilteritinib levels.
Mean concentrations of CDCA-24G were assessed, showing significant changes with TL-895 treatment.
This study used C57BL/6 and NSG mice models to illustrate DDI liabilities induced by TL-895.
Findings may guide further research in optimizing drug regimens involving BTK inhibitors.

Implication

Evaluation of drug-drug interactions with TL-895 in mice, highlighting impacts on gilteritinib and pravastatin.

Abstract

Assessment of DDI liabilities induced by TL-895. Influence of TL-895 (3 mg/kg) on circulating concentrations of CDCA-24G (A), oral (20 mg/kg) pravastatin (B), or oral (30 mg/kg) gilteritinib in C57BL/6 mice (C) and NSG mice (D). Data represent mean values (symbols) and SD (error bars) using 4 or 5 animals per group.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stromatt et al. (2025) studied this question.

synapsesocial.com/papers/68d4605131b076d99fa5fa74 https://doi.org/10.1158/2767-9764.30111356

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading